Pure Transplant Solutions and King's College London to Support Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease
AUSTIN, Texas /Massachusetts Newswire – National News/ — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King’s College London, a leading university providing world-class teaching and cutting-edge research, to support the Phase IIa GAMECHANgER-1 clinical trial. The trial aims to determine whether adoptive transfer of regulatory T cells (Tregs) in...
Source: massachusettsnewswire.com